A large-scale study of nearly 450,000 women indicates that combining GLP-1 receptor agonists with progestin therapy significantly lowers the risk of endometrial cancer. This protective effect was observed in women with benign uterine disease or endometrial hyperplasia.
The analysis, drawing from extensive electronic health records, found that patients receiving the combination therapy experienced a markedly reduced risk of developing endometrial cancer compared to those on progestin monotherapy. This benefit remained consistent across various patient subgroups, suggesting broad applicability.
Further findings showed that adding GLP-1 receptor agonists to progestin and even metformin therapy provided additional risk reduction for endometrial cancer. This suggests optimizing endometrial protection through integrated hormonal management, particularly for patients with metabolic risk factors.
Beyond cancer risk reduction, the combined therapy was also linked to lower rates of subsequent hysterectomies at both two and five-year intervals. These results point to a promising, less invasive approach for managing endometrial health and mitigating cancer risk.